Geographic and Product Information (Tables)

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Schedule of revenues and long-lived assets by geographic area

Revenues	2014		2013		2012
United States	$	4,482.8	$	3,862.1	$	3,169.1
Europe	2,310.8		1,865.7		1,617.7
All other	876.8		766.1		719.9
Total revenues	$	7,670.4	$	6,493.9	$	5,506.7

Long-Lived Assets1	2014		2013
United States	$	406.1	$	348.0
Europe	222.2		230.4
All other	14.3		15.0
Total long lived assets	$	642.6	$	593.4

¹  Long-lived assets consist of net property, plant and equipment.

Schedule of total revenues from external customers by product

Total revenues from external customers by product for the years ended December 31, 2014, 2013 and 2012 were as follows:

	2014		2013		2012
REVLIMID®	$	4,980.0	$	4,280.3	$	3,766.6
ABRAXANE®	848.2		648.9		426.7
POMALYST®/IMNOVID®	679.7		305.4		12.0
VIDAZA®	611.9		803.3		823.2
azacitidine for injection	78.2		23.3		—
THALOMID®	221.2		244.5		302.1
OTEZLA®	69.8		—		—
ISTODAX®	65.6		54.0		50.0
Other	9.2		2.6		5.0
Total net product sales	7,563.8		6,362.3		5,385.6
Other revenue	106.6		131.6		121.1
Total revenue	$	7,670.4	$	6,493.9	$	5,506.7

Schedule of customer concentration risk based on total revenues and net accounts receivable

The percentage of amounts due from this customer compared to total net accounts receivable is also summarized below as of December 31, 2014 and 2013.

	Percent of Total Revenue						Percent of Net Accounts Receivable
Customer	2014		2013		2012		2014		2013
Amerisource Bergen Corp.	4.2	%	10.7	%	11.5	%	3.6	%	6.4	%